Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05283603
Recruiting Observational

Clinical Observational Registry of Patients With Left Bundle Branch Block

NCT05283603 · tracked via the Priya Life Science Italy tracker
Sponsor
Azienda Ospedaliero Universitaria di Sassari
Phase
Observational
Started
2019-07-31
Last updated
2022-03-17

Condition(s) studied

Left Bundle Branch Block (LBBB) on ECG

Investigational drug(s) / intervention(s)

ECG, Echocardiogram, Magnetic resonance

ECG, Echocardiogram, Magnetic resonance: Clinical and instrumental follow-up

Study summary

The electromechanical dyssynchrony induced by the presence of LBBB is in some patients, but not all, the cause of progressive left ventricular systolic dysfunction and heart failure.

Aims

1. To investigate the clinical, ECG, imaging-derived features in a large cohort of patients affected by LBBB on ECG.
2. To identify predictors of LBBB-induced LV systolic dysfunction and predictors of outcome in this population.
3. To derive data which may have an impact on therapeutic management.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * LBBB on ECG Exclusion Criteria: * Previous extensive anterior myocardial infarction * Previous cardiac surgery or transcatheter aortic valve implantation (TAVI) * Congenital structural heart disease * Patients implanted with permanent right ventricular stimulation devices and permanent pacing * Denial to consent

Primary outcome measure(s)

  • Left ventricular dysfunction — 20 years
    Echocardiographic left ventricular ejection fraction - EF (%)

Trial sites (1)

FacilityCityRegionStatus
Cardiology, AOU Sassari Sassari Italy Recruiting

More Azienda Ospedaliero Universitaria di Sassari trials in Italy

Virtual Reality-Based Cardiac Rehabilitation in Patients Undergoing Cardiac Surgery Starting soon
Music Medicine in Coronary Interventional Cardiology Procedures Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05283603 on ClinicalTrials.gov ↗ ← All trials in Italy